¹⁷⁷Lu-DOTA-HYNIC-Lys(Nal)-Urea-Glu: Biokinetics, Dosimetry, and Evaluation in Patients with Advanced Prostate Cancer

Table 3

Average total number of disintegrations (N) in source organs, organ-absorbed doses, and effective dose of ¹⁷⁷Lu-iPSMA, calculated from five healthy subjects (men).

Target organ	N (mean ± SD)	Organ doses (Gy/GBq)
	(MBq·h/MBq)	Average	SD
Adrenals	—	0.030	0.007
Brain	—	0.024	0.005
Breasts	—	0.024	0.004
Gallbladder wall	—	0.032	0.006
LLI wall	—	0.041	0.011
Small intestine	0.300 ± 0.018	0.027	0.006
Stomach wall	—	0.027	0.006
ULI wall	—	0.044	0.010
Heart wall	—	0.049	0.005
Kidneys	2.953 ± 0.475	0.880	0.040
Liver	6.322 ± 0.352	0.280	0.090
Lungs	0.400 ± 0.098	0.030	0.010
Muscle	—	0.025	0.006
Ovaries	—	0.040	0.010
Pancreas	—	0.030	0.007
Red marrow	—	0.030	0.010
Osteogenic cells	—	0.077	0.017
Skin	—	0.024	0.004
Spleen	0.450 ± 0.036	0.232	0.070
Testes	—	0.025	0.006
Thymus	—	0.025	0.004
Thyroid	—	0.024	0.007
Salivary glands	0.225 ± 0.005	1.170	0.310
Lacrimal glands	0.041 ± 0.013	1.321	0.091
Urinary bladder wall	—	0.249	0.103
Urinary bladder	1.369 ± 0.441	—	—
Uterus	—	0.028	0.007
Remainder of the body	19.380 ± 1.550	—	—
Total body	—	0.040	0.021